CDC: Prevalence of No Insurance Varies by Occupational Groups
Significant drop in prevalence of uninsured from 2013 to 2014; variation by occupation in both years
Reasons for nondisclosure include not wanting to be judged or lectured, being embarrassed
Funding Opportunity RFA-AI-18-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States and Brazil under the U.S.-Brazil Biomedical Collaborative Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; cancer; mother-to-child transmission of HIV and other congenital infections, early infant diagnosis and treatment; HIV/AIDS in relation to mental health; and neurological disorders and stroke.
Condition: HIV Infections Interventions: Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets; Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Maternal Pediatric Adolescent AIDS Clinical Trials Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); ViiV Hea lthcare Ltd. Not yet recruiting
Coverage gains did not negatively impact employment levels, hours worked, earnings
An effective human immunodeficiency virus type 1 (HIV-1) vaccine has long been sought to contend with the Acquired Immunodeficiency Syndrome (AIDS) pandemic.One approach researchers have taken to elicit broadly neutralizing antibodies against HIV-1 is to stabilize the structurally flexible HIV-1 envelope (Env) trimer. Researchers stabilized the Env trimer in a conformation that displays predominantly broadly neutralizing epitopes and few non-neutralizing epitopes. Currently, BG505 DS-SOSIP is a leading vaccine candidate with the desired conformation and antigenicity.Ideally, to be useful as a vaccine, such a conformational...
Fractional exhaled nitric oxide (FeNO) is a direct marker of Type 2 (T2)-driven inflammation in the airways and aids in the diagnosis of asthma.1, 2 FeNO is reproducible and easy to use in the clinic setting.3 - 5 FeNO measurement technique is often easier for younger children to master than spirometry6 and much less invasive than sputum induction or bronchoscopy.7, 8
This technology is a set of influenza virus enrichment probes developed to increase the sensitivity of sequence-based, universal detection of all influenza viruses. This universal influenza enrichment probe set contains a unique set of 46,953 biotin-labeled, RNA probes, each 120 base-pairs long, that can be used to enrich for any influenza sequences without prior knowledge of type or subtype. This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus ma...
Robert R. Redfield, M.D., director of the Centers for Disease Control and Prevention (CDC), will deliver the 2018 Joseph J. Kinyoun Memorial Lecture on the intersection between the national opioid crisis and the management of infectious diseases. Titled, “ Opioids: Epidemic of Our Time and Impact on Infectious Disease, ” Dr. Redfield ’ s talk will explore the impacts of the unprecedented use of opioids in the United States on the management of infectious diseases. While overdose remains the leading cause of death among people who use opioids, this population is also disproportionately affected by viral he...
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ~35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combin...
Insurers are expanding their participation in the program
More News: Allergy | Allergy & Immunology | Brain | Cancer & Oncology | Cardiology | Dermatology | Emergency Medicine | Endocrinology | Gastroenterology | Geriatrics | Heart | HIV AIDS | Insurance | Internal Medicine | Neurology | Nurses | Nursing | Occupational Health | Opthalmology | Orthopaedics | Respiratory Medicine | Skin | Uninsured | Urology & Nephrology